Long-term outcomes and improved risk of revision following tumor endoprosthetic replacement of the distal femur: Single institutional results.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 34177190.
- Also identified by DOI 10.1016/j.jor.2021.05.027 and PMC identifier 8212066.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study assessed revision characteristics following distal femur tumor endoprosthetic replacement. Fifty-seven procedures were performed between 2005 and 2019. The cumulative incidence of implant revision was calculated with death as a competing risk. The all-cause revision rate was 21.1% (n = 12) at a mean 65.3 ± 47.3 months. Competing risk analysis revealed a cumulative revision incidence of 12.0% (95% CI, 3.6-25.9%) at five years and 36.5% (95% CI, 12.8-61.0%) at ten years. We provide an accurate assessment of revision risk which is slightly lower than historical controls, with identification of failure modes to reliably inform patient expectations. III. Retrospective Study.
Anatomy
- femur